These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 1362997

  • 1. Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression.
    Benkert O, Gründer G, Wetzel H.
    Pharmacopsychiatry; 1992 Nov; 25(6):254-60. PubMed ID: 1362997
    [Abstract] [Full Text] [Related]

  • 2. Dopamine autoreceptor agonists in the treatment of schizophrenic disorders.
    Wetzel H, Benkert O.
    Prog Neuropsychopharmacol Biol Psychiatry; 1993 Jul; 17(4):525-40. PubMed ID: 8103233
    [Abstract] [Full Text] [Related]

  • 3. Dopamine agonists in schizophrenia: a review.
    Benkert O, Müller-Siecheneder F, Wetzel H.
    Eur Neuropsychopharmacol; 1995 Jul; 5 Suppl():43-53. PubMed ID: 8775758
    [Abstract] [Full Text] [Related]

  • 4. [Dopanergic agonists and schizophrenia].
    Pidgeon JF, Wolf MA.
    Psychiatr J Univ Ott; 1989 Nov; 14(4):529-35. PubMed ID: 2573101
    [Abstract] [Full Text] [Related]

  • 5. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist.
    Bartoszyk GD, Harting J, Minck KO.
    J Pharmacol Exp Ther; 1996 Jan; 276(1):41-8. PubMed ID: 8558454
    [Abstract] [Full Text] [Related]

  • 6. Dopamine, depression and antidepressants.
    Dailly E, Chenu F, Renard CE, Bourin M.
    Fundam Clin Pharmacol; 2004 Dec; 18(6):601-7. PubMed ID: 15548230
    [Abstract] [Full Text] [Related]

  • 7. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A.
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [Abstract] [Full Text] [Related]

  • 8. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms.
    Wetzel H, Hillert A, Gründer G, Benkert O.
    Am J Psychiatry; 1994 Oct; 151(10):1499-502. PubMed ID: 7916543
    [Abstract] [Full Text] [Related]

  • 9. Partial brain dopamine D2 receptor agonists in the treatment of schizophrenia.
    Coward D, Dixon K, Enz A, Shearman G, Urwyler S, White T, Karobath M.
    Psychopharmacol Bull; 1989 Oct; 25(3):393-7. PubMed ID: 2576320
    [Abstract] [Full Text] [Related]

  • 10. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
    Jeziorski M, White FJ.
    Synapse; 1989 Oct; 4(4):267-80. PubMed ID: 2603146
    [Abstract] [Full Text] [Related]

  • 11. Antipsychotic efficacy of the dopaminergic autoreceptor agonist EMD 49980 (Roxindol). Results of an open clinical study.
    Klimke A, Klieser E.
    Pharmacopsychiatry; 1991 Jul; 24(4):107-12. PubMed ID: 1684439
    [Abstract] [Full Text] [Related]

  • 12. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence.
    Schmidt K, Nolte-Zenker B, Patzer J, Bauer M, Schmidt LG, Heinz A.
    Pharmacopsychiatry; 2001 Mar; 34(2):66-72. PubMed ID: 11302566
    [Abstract] [Full Text] [Related]

  • 13. Serotonergic modulation of dopamine neurotransmission: a mechanism for enhancing therapeutics in schizophrenia.
    Haleem DJ.
    J Coll Physicians Surg Pak; 2006 Aug; 16(8):556-62. PubMed ID: 16899192
    [Abstract] [Full Text] [Related]

  • 14. B-HT 920--a novel dopamine autoreceptor agonist in the treatment of patients with schizophrenia.
    Wiedemann K, Benkert O, Holsboer F.
    Pharmacopsychiatry; 1990 Jan; 23(1):50-5. PubMed ID: 1969167
    [Abstract] [Full Text] [Related]

  • 15. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Jan; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 16. [Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
    Shiloh R, Weizman A, Weizer N, Dorfman-Etrog P, Munitz H.
    Harefuah; 2001 May; 140(5):369-73, 456. PubMed ID: 11419053
    [Abstract] [Full Text] [Related]

  • 17. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
    Potvin S, Stip E, Roy JY.
    Encephale; 2003 May; 29(3 Pt 1):193-203. PubMed ID: 12876543
    [Abstract] [Full Text] [Related]

  • 18. [Functional role of dopamine D3 receptor in schizophrenia].
    Semba J.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):3-11. PubMed ID: 15027325
    [Abstract] [Full Text] [Related]

  • 19. Electrophysiological effects of putative autoreceptor-selective dopamine agonists on A10 dopamine neurons.
    Ackerman JM, Johansen PA, Clark D, White FJ.
    J Pharmacol Exp Ther; 1993 May; 265(2):963-70. PubMed ID: 8098768
    [Abstract] [Full Text] [Related]

  • 20. Pharmacology of mesocortical dopamine neurons.
    Bannon MJ, Roth RH.
    Pharmacol Rev; 1983 Mar; 35(1):53-68. PubMed ID: 6138783
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.